The FDA approved isatuximab-irfc (Sarclisa, Sanofi Genzyme) in combination with carfilzomib (Kyprolis, Amgen) and dexamethasone (Kd) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received one to three prior lines of therapy.
The approval “is an important advancement for patients whose disease has relapsed and reinforces the potential for [isatuximab] to become a standard of care in relapsed or refractory multiple myeloma,” said